CagriSema for Weight Loss: Trial Results, Mechanism, and Status (2026)
Evidence-informed CagriSema guide covering REDEFINE trial weight-loss results, the cagrilintide + semaglutide mechanism, tirzepatide comparison, side effects, and FDA status.
PeakedLabs editorial standard. We organize provider, pricing, lab-monitoring, and safety signals for research. This is not medical advice; use it to prepare better questions for a licensed clinician.
Executive Summary
CagriSema is an investigational once-weekly weight-loss injection that combines the amylin analogue cagrilintide 2.4 mg with semaglutide 2.4 mg, and it produced about 22-23% average weight loss in its REDEFINE trials. That places it among the most effective agents studied, though in a head-to-head it narrowly missed proving noninferiority to tirzepatide.
The combination is the story. Amylin (via cagrilintide) and GLP-1 (via semaglutide) work through different appetite pathways, and pairing them produced more weight loss than either component alone - 22.7% for CagriSema versus 16.1% for semaglutide and 11.8% for cagrilintide in REDEFINE 1. It is a different route to high efficacy than the GLP-1/GIP dual agonism of tirzepatide.
Use this guide with semaglutide, tirzepatide, and compare providers so you understand where CagriSema may fit once it is available.
Free decision tools
Turn the research into a provider shortlist
Compare published pricing, lab models, clinician access, treatment focus, and state coverage before you enroll. PeakedLabs scoring stays independent from commercial relationships.
At-a-Glance Comparison
CagriSema at a glance - a high-efficacy amylin + GLP-1 combination still awaiting a regulatory decision.
| Factor | CagriSema | Comparators | Practical Takeaway |
|---|---|---|---|
| Components | Cagrilintide 2.4mg + semaglutide 2.4mg | Single/dual agonists | Amylin + GLP-1 combination |
| REDEFINE 1 weight loss | 22.7% | 16.1% semaglutide alone | Combo beats either component |
| vs tirzepatide (REDEFINE 4) | 23.0% | 25.5% tirzepatide | Missed noninferiority narrowly |
| FDA status (2026) | Under review | Approved comparators exist | Decision expected late 2026 |
How CagriSema Works: Amylin Meets GLP-1
Searchers want to know why combining two drugs matters, and the mechanism explains the strong results.
CagriSema pairs cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 agonist. Amylin and GLP-1 influence satiety and food intake through complementary pathways, so combining them adds appetite suppression beyond what either delivers alone. This is a distinct strategy from tirzepatide's GLP-1/GIP dual agonism. For the broader mechanism context, see the complete peptide therapy guide.
Common failure mode: buyers assume all high-efficacy weight-loss drugs work the same way and miss that mechanism affects tolerability and fit.
Execution Checklist
- Understand amylin and GLP-1 act on different pathways.
- Note this differs from GLP-1/GIP dual agonists.
- Match mechanism to your response history.
- Discuss combination therapy with a clinician.
The Trial Results in Context
The REDEFINE program is impressive but nuanced, and the tirzepatide comparison is widely misread.
In REDEFINE 1, CagriSema achieved 22.7% weight loss with 60% of participants losing at least 20%. In REDEFINE 4, it reached 23.0% but did not meet its primary endpoint of noninferiority to tirzepatide 15 mg (23.0% vs 25.5% under one estimand). 'Missed noninferiority' is a statistical result, not a failure - CagriSema still delivered high-tier weight loss. Compare against tirzepatide to see where each lands.
Common failure mode: readers interpret 'missed noninferiority vs tirzepatide' as 'does not work,' which misrepresents 23% weight loss.
Execution Checklist
- Read 'missed noninferiority' as a statistical margin.
- Note CagriSema still delivered ~23% weight loss.
- Compare estimands, not just headline numbers.
- Treat cross-trial comparisons cautiously.
Side Effects and Tolerability
Combining two appetite-acting drugs raises reasonable questions about tolerability.
As a semaglutide-containing combination, CagriSema's side effects are predominantly gastrointestinal - nausea, vomiting, and related GI effects - consistent with the GLP-1 class and generally managed with titration. Because weight loss is substantial, muscle-preservation habits apply: resistance training and 1.2-1.6 g/kg protein daily. Any use should be clinician-supervised via compare providers once available.
Common failure mode: patients underestimate GI side effects of a combination product and stop before titration stabilizes them.
Execution Checklist
- Expect GLP-1-class GI side effects.
- Rely on slow titration for tolerability.
- Protect muscle during rapid weight loss.
- Report persistent symptoms to your clinician.
Availability and What to Do Now
CagriSema is not yet a prescription option, so the practical question is what to do in the meantime.
CagriSema was submitted to the FDA in December 2025 based on REDEFINE 1 and 2, with a decision anticipated by late 2026 - it is not available to prescribe today. If you need treatment now, approved options like tirzepatide and semaglutide are the realistic path; keep CagriSema on your radar and revisit once it clears review. Avoid gray-market 'cagrilintide' or combination vials of unknown origin. Start your comparison at compare providers.
Common failure mode: buyers chase unapproved CagriSema components from unverified sellers and take on purity and dosing risk.
Execution Checklist
- Recognize CagriSema is not yet prescribable.
- Use approved GLP-1 options if you need to start now.
- Avoid gray-market combination products.
- Re-evaluate once the FDA decision lands.
Internal Resources to Compare Next
Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.
Compare Providers Before You Purchase
CagriSema is a genuinely strong combination that just happened to run into an even stronger comparator. If you need treatment now, use an approved GLP-1; if you can wait, watch for the late-2026 decision - and never source unapproved vials.
Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.
Frequently Asked Questions
What is CagriSema?
CagriSema is an investigational once-weekly weight-loss injection combining the amylin analogue cagrilintide 2.4 mg with semaglutide 2.4 mg. It produced about 22-23% average weight loss in its REDEFINE trials.
How much weight can you lose on CagriSema?
In REDEFINE 1, CagriSema produced 22.7% average weight loss, with 60% of participants losing at least 20%. REDEFINE 4 showed 23.0% at 84 weeks - high-tier efficacy for weight management.
Is CagriSema better than tirzepatide?
In the REDEFINE 4 head-to-head, CagriSema (23.0%) did not meet noninferiority versus tirzepatide 15 mg (25.5%). It still delivered strong weight loss, but tirzepatide edged it in that comparison.
Is CagriSema FDA approved?
Not yet. It was submitted to the FDA in December 2025 based on REDEFINE 1 and 2, with a regulatory decision anticipated by late 2026. It is not available to prescribe today.
What are CagriSema's side effects?
As a semaglutide-containing combination, side effects are predominantly gastrointestinal - nausea, vomiting, and related GI effects - consistent with the GLP-1 class and generally managed with slow dose titration.
What should I use while waiting for CagriSema?
If you need treatment now, approved options like tirzepatide and semaglutide are the realistic path. Avoid gray-market cagrilintide or combination vials, and revisit CagriSema once it clears FDA review.
Read next
GLP-1 Microdosing: What Low-Dose Semaglutide and Tirzepatide Actually Do
GLP-1 microdosing means using doses below the studied therapeutic range. Here is what the dose-response data implies, why patients try it, and how to vet a provider offering low-dose protocols.
Retatrutide Microdosing: What It Means and What the Evidence Supports
Retatrutide microdosing is an experimental dosing approach applied to an experimental drug. Here is how to think about it without confusing anecdote for evidence.
Retatrutide FDA Approval Status (2026): Timeline, Trial Data, and What To Do Now
Retatrutide is not FDA approved. Here is the real regulatory timeline, what the Phase 3 trials showed, and what to use in the meantime instead of buying it from a research vendor.
The newsletter
Get the latest peptide & TRT research
Weekly evidence-based updates on protocols, costs, and telehealth provider quality.
Free forever. Unsubscribe anytime. We never sell your email.